Clopidogrel ratiopharm GmbH

RSS
Withdrawn

This medicine's authorisation has been withdrawn

clopidogrel
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 13 January 2020, the European Commission withdrew the marketing authorisation for Clopidogrel ratiopharm GmbH (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Archie Samuel s.r.o., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Clopidogrel ratiopharm GmbH was granted marketing authorisation in the EU on 28 July 2009 for prevention of atherothrombotic events. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. 

Clopidogrel ratiopharm GmbH is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU. 

The European Public Assessment Report (EPAR) for Clopidogrel ratiopharm GmbH is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (748.14 KB - PDF)

View

español (ES) (699.21 KB - PDF)

View

čeština (CS) (774.98 KB - PDF)

View

dansk (DA) (698.71 KB - PDF)

View

Deutsch (DE) (699.89 KB - PDF)

View

eesti keel (ET) (698.1 KB - PDF)

View

ελληνικά (EL) (816.71 KB - PDF)

View

français (FR) (697.65 KB - PDF)

View

italiano (IT) (736.11 KB - PDF)

View

latviešu valoda (LV) (717.15 KB - PDF)

View

lietuvių kalba (LT) (696.28 KB - PDF)

View

magyar (HU) (748.24 KB - PDF)

View

Malti (MT) (773.38 KB - PDF)

View

Nederlands (NL) (699.22 KB - PDF)

View

polski (PL) (774.48 KB - PDF)

View

português (PT) (639.16 KB - PDF)

View

română (RO) (664.03 KB - PDF)

View

slovenčina (SK) (771.09 KB - PDF)

View

slovenščina (SL) (766.49 KB - PDF)

View

Suomi (FI) (692.08 KB - PDF)

View

svenska (SV) (698.39 KB - PDF)

View

Product information

български (BG) (2.02 MB - PDF)

View

español (ES) (1.05 MB - PDF)

View

čeština (CS) (1.71 MB - PDF)

View

dansk (DA) (1.05 MB - PDF)

View

Deutsch (DE) (1.08 MB - PDF)

View

eesti keel (ET) (1.07 MB - PDF)

View

ελληνικά (EL) (2.07 MB - PDF)

View

français (FR) (1.12 MB - PDF)

View

hrvatski (HR) (1.14 MB - PDF)

View

íslenska (IS) (1.04 MB - PDF)

View

italiano (IT) (1.06 MB - PDF)

View

latviešu valoda (LV) (1.71 MB - PDF)

View

lietuvių kalba (LT) (1.15 MB - PDF)

View

magyar (HU) (1.81 MB - PDF)

View

Malti (MT) (1.93 MB - PDF)

View

Nederlands (NL) (1.08 MB - PDF)

View

norsk (NO) (1.03 MB - PDF)

View

polski (PL) (960.36 KB - PDF)

View

português (PT) (1.05 MB - PDF)

View

română (RO) (1.2 MB - PDF)

View

slovenčina (SK) (1.68 MB - PDF)

View

slovenščina (SL) (1.64 MB - PDF)

View

Suomi (FI) (886.54 KB - PDF)

View

svenska (SV) (1.1 MB - PDF)

View
Latest procedure affecting product information: IAIN/0036
22/08/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (1.2 MB - PDF)

View

español (ES) (1.12 MB - PDF)

View

čeština (CS) (1.19 MB - PDF)

View

dansk (DA) (1.12 MB - PDF)

View

Deutsch (DE) (1.12 MB - PDF)

View

eesti keel (ET) (1.12 MB - PDF)

View

ελληνικά (EL) (1.2 MB - PDF)

View

français (FR) (1.12 MB - PDF)

View

italiano (IT) (1.12 MB - PDF)

View

latviešu valoda (LV) (1.2 MB - PDF)

View

lietuvių kalba (LT) (1.18 MB - PDF)

View

magyar (HU) (1.2 MB - PDF)

View

Malti (MT) (1.19 MB - PDF)

View

Nederlands (NL) (1.12 MB - PDF)

View

polski (PL) (1.16 MB - PDF)

View

português (PT) (1.12 MB - PDF)

View

română (RO) (1.18 MB - PDF)

View

slovenčina (SK) (1.16 MB - PDF)

View

slovenščina (SL) (1.13 MB - PDF)

View

Suomi (FI) (1.12 MB - PDF)

View

svenska (SV) (1.12 MB - PDF)

View

Product details

Name of medicine
Clopidogrel ratiopharm GmbH
Active substance
clopidogrel
International non-proprietary name (INN) or common name
clopidogrel
Therapeutic area (MeSH)
  • Peripheral Vascular Diseases
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Stroke
Anatomical therapeutic chemical (ATC) code
B01AC04

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

  • patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;
  • patients suffering from acute coronary syndrome:
    • non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q wave-myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
    • ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Authorisation details

EMA product number
EMEA/H/C/001165

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Archie Samiel s.r.o.

Slunná 16
61700 Brno
Czech Republic

Marketing authorisation issued
28/07/2009
Withdrawal of marketing authorisation
13/01/2020
Revision
12

Assessment history

This page was last updated on

Share this page